yttrium-90 labetuzumab

Radiolabeled humanized monoclonal antibody targeting carcinoembryonic antigen (CEA), conjugated with the radioisotope yttrium-90. Mechanistically, it enables targeted delivery of ionizing radiation to CEA-expressing tumor cells, acting as a radiopharmaceutical and antineoplastic agent for cancers such as colorectal and pancreatic cancer. Developed primarily for radioimmunotherapy, its originator is Immunomedics; as of October 2020, Immunomedics has been acquired by Gilead Sciences[1][4][6][7][10].

Brand names

CEA-Cide-Y-90CEA-Cide-Y90CEA-Cide-Y 90

Other names

yttrium-90 labetuzumabyttrium90 labetuzumabyttrium 90 labetuzumabYttrium Y 90 labetuzumabYttrium Y-90 Labetuzumab TetraxetanAnti-CEA monoclonal antibody MN 14-Y-90